BioSpace News Archive

Mevion Medical Systems is delighted to be selected to participate in the proton therapy initiative between the city of Córdoba in Andalusia, Spain, the Ministry of Health and Families of Andalusia, and the University of Córdoba to establish an alliance with the Andalusian Health Service and the University Institution.

Humanigen, Inc. , (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11th, 2020 at 2:00 pm Eastern Time. The conference is being

Charles River Laboratories International, Inc. reported its results for the second quarter of 2020.

—“Process B” Demonstrates Safety and Sustained Efficacy for FA (RP-L102) and LAD-I (RP-L201)— —First Patient Treated in Global Phase 1 Study of RP-L301 for PKD— —FDA Clearance of IND for IMO (RP-L401) — —Preliminary Data Readouts in Danon and PKD and Additional “Process B” Data in FA and LAD-I on Track for Fourth Quarter— —Strong Balance Sheet with $250 Million in Cash; Capitalized into 2Q 2022— NEW YORK--( BUSINESS WIRE

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb 2 ™) antibodies, today announces that Eliot Forster, Chief Executive Officer, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on Monday August 10, 2020. Event : F-star

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, reported financial results and provided business updates for the second quarter of 2020 and highlighted pipeline progress.

TRACK Research Study Designed to Provide Genomically-Informed Treatment Recommendations to Patients while Advancing Genomic Characterization of Rare Cancers

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences

-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –- -- Initiated Phase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of 2020 –- -- Raised Gross Proceeds of $22.7M Through Two Public Offerings, Extending Cash Runway Beyond the Second Quarter of 2021 –-

Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report second quarter 2020 financial results on Wednesday, August 12, 2020 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows